VERAXA Biotech (NASDAQ: VRXA) is making strides in the development of antibody-based cancer therapies, leveraging its proprietary BiTAC platform to create bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). The company’s approach focuses on dual-targeting, an ‘AND-gated’ architecture that aims to activate therapeutic effects primarily at tumor sites, potentially reducing off-target toxicity and improving efficacy.
The company recently announced that its lead BiTAC-TCE candidate has advanced toward IND/CTA-enabling activities, following successful cell-line development and regulatory feedback from Germany’s Paul-Ehrlich-Institute. This milestone marks a significant step forward in the preclinical development of this therapy, which is designed to engage T-cells to attack cancer cells expressing two specific antigens.
In parallel, VERAXA’s VXA-222, a bispecific ADC, has moved beyond the initial discovery phase after the completion of the antibody-discovery step with OmniAb. The company is now responsible for engineering the final therapeutic candidate using the antibody binders generated through this collaboration. ADCs are designed to deliver cytotoxic drugs directly to cancer cells, and the bispecific nature of VXA-222 aims to enhance tumor selectivity.
VERAXA’s intellectual property portfolio includes more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, along with additional pending applications. This robust IP position underscores the company’s commitment to protecting its innovative platform and pipeline.
The BiTAC platform is central to VERAXA’s strategy, as it is designed to recognize two distinct antigens on cancer cells, thereby increasing the likelihood of binding to tumor cells while sparing healthy tissue. This ‘AND-gate’ logic ensures that the therapeutic effect is triggered only when both targets are present, which is a key differentiator from conventional monospecific antibodies.
The advancement of VXA-222 and the BiTAC-TCE highlights VERAXA’s progress in building a diversified oncology pipeline. The company’s focus on bispecific ADCs and TCEs aligns with broader industry trends toward more precise cancer therapies that aim to improve patient outcomes.
Investors and industry observers are closely monitoring VERAXA’s pipeline developments, as the company seeks to establish itself in the competitive field of cancer immunotherapy. With its proprietary platform and recent milestones, VERAXA is positioning itself to address significant unmet medical needs in oncology.
For more information on VERAXA Biotech and its pipeline, visit the company’s newsroom at https://nnw.fm/VRXA.
